WO2011045454A3 - Multifunctional nanostructures as spect/mri bimodal diagnosis agents - Google Patents

Multifunctional nanostructures as spect/mri bimodal diagnosis agents Download PDF

Info

Publication number
WO2011045454A3
WO2011045454A3 PCT/ES2010/000424 ES2010000424W WO2011045454A3 WO 2011045454 A3 WO2011045454 A3 WO 2011045454A3 ES 2010000424 W ES2010000424 W ES 2010000424W WO 2011045454 A3 WO2011045454 A3 WO 2011045454A3
Authority
WO
WIPO (PCT)
Prior art keywords
spect
nanostructures
multifunctional
diagnosis agents
diagnosis
Prior art date
Application number
PCT/ES2010/000424
Other languages
Spanish (es)
French (fr)
Other versions
WO2011045454A2 (en
Inventor
José Manuel DOMÍNGUEZ VERA
Natividad GÁLVEZ RODRÍGUEZ
Belén FERNÁNDEZ LÓPEZ
Elsa Valero Romero
José Juan CALVINO GÁMEZ
Susana Trasobares Llorente
Original Assignee
Universidad De Granada
Universidad De Cádiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Granada, Universidad De Cádiz filed Critical Universidad De Granada
Publication of WO2011045454A2 publication Critical patent/WO2011045454A2/en
Publication of WO2011045454A3 publication Critical patent/WO2011045454A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Abstract

The invention relates to multifunctional nanostructures consisting of superparamagnetic magnetoferritin which can also comprise chains of a biocompatible polymer covalently bound to the surface thereof. The invention also relates to a method for obtaining said nanostructures, as well as to the use thereof as a drug, preferably for the diagnosis of cancer or as a contrast agent.
PCT/ES2010/000424 2009-10-14 2010-10-13 Multifunctional nanostructures as spect/mri bimodal diagnosis agents WO2011045454A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200930845 2009-10-14
ES200930845A ES2367190B1 (en) 2009-10-14 2009-10-14 MULTIFUNCTIONAL Nanostructures AS MRI-SPECT BIMODAL DIAGNOSIS AGENTS.

Publications (2)

Publication Number Publication Date
WO2011045454A2 WO2011045454A2 (en) 2011-04-21
WO2011045454A3 true WO2011045454A3 (en) 2011-06-09

Family

ID=43876632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/000424 WO2011045454A2 (en) 2009-10-14 2010-10-13 Multifunctional nanostructures as spect/mri bimodal diagnosis agents

Country Status (2)

Country Link
ES (1) ES2367190B1 (en)
WO (1) WO2011045454A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491219A (en) * 1993-06-11 1996-02-13 Protein Magnetics Ferritin with ferrimagnetically ordered ferrite core and method technical field
US20070258888A1 (en) * 2003-11-17 2007-11-08 Claus Feldmann Contrast Agent for Medical Imaging Techniques and Usage Thereof
WO2008115854A2 (en) * 2007-03-19 2008-09-25 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Multifunctional nanoparticles and compositions and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491219A (en) * 1993-06-11 1996-02-13 Protein Magnetics Ferritin with ferrimagnetically ordered ferrite core and method technical field
US20070258888A1 (en) * 2003-11-17 2007-11-08 Claus Feldmann Contrast Agent for Medical Imaging Techniques and Usage Thereof
WO2008115854A2 (en) * 2007-03-19 2008-09-25 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Multifunctional nanoparticles and compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOMINIC P.E. DICKSON: "Nanostructured magnetism in living systems", JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, vol. 203, 1999, pages 46 - 49 *
MASAKI UCHIDA ET AL.: "A human ferritin iron oxide nano-composite magnetic resonance contrast agent", MAGNETIC RESONANCE IN MEDICINE, vol. 60, 2008, pages 1073 - 1081, XP055202896, DOI: doi:10.1002/mrm.21761 *
P. E. DICKSON ET AL.: "Properties of magnetoferritin: a novel biomagnetic nanoparticle", NANOSTRUCTURED MATERIALS, vol. 9, 1997, pages 595 - 598, XP026067410, DOI: doi:10.1016/S0965-9773(97)00133-5 *

Also Published As

Publication number Publication date
WO2011045454A2 (en) 2011-04-21
ES2367190A1 (en) 2011-10-31
ES2367190B1 (en) 2013-01-22

Similar Documents

Publication Publication Date Title
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EA201290498A1 (en) THERAPEUTIC POLYMER NANOPARTICLES, INCLUDING EPOTILON, AND METHODS FOR THEIR PREPARATION AND APPLICATION
WO2009140423A3 (en) Targeted polymer bioconjugates
EP2915818A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2012054638A3 (en) Nmr systems and methods for the detection of analytes
WO2010138194A3 (en) Immunomodulatory agent-polymeric compounds
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
ZA201106983B (en) Soluble "heavy-chain only" antibodies
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2011028811A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2011050262A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2011047262A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2011014659A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2010127284A3 (en) Dual variable domain immunoglobulins and uses thereof
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010097186A8 (en) Use of s-erbb-3 as a marker for cancer
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
HRP20171443T1 (en) Process for the preparation of iodinated contrast agent
AP2012006182A0 (en) Detecting PAX2 for the diagnosis of breast cancer.
PT2149372E (en) Use of opioids of the methadone group for the treatment of resistant cancer patients
WO2010017153A3 (en) Medical devices and methods including blends of biodegradable polymers
WO2010037042A3 (en) Methods for detecting and treating cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10823090

Country of ref document: EP

Kind code of ref document: A2